Familial chylomicronemia: New perspectives.

Area of Science:

• Genetics
• Metabolic Disorders
• Pharmacology

Background:

• Familial chylomicronemia syndrome (FCS) is a rare, underdiagnosed genetic disorder.
• It leads to severe symptoms like abdominal pain, recurrent pancreatitis, diabetes mellitus, and exocrine pancreatic insufficiency.
• FCS significantly impacts patients' quality of life and mental health.

Purpose of the Study:

• To review the current understanding of Familial chylomicronemia syndrome.
• To discuss the challenges in managing FCS, particularly the difficulties with strict low-fat diets.
• To evaluate emerging pharmacological treatments for reducing triglyceride levels in FCS patients.

Main Methods:

• Literature review of Familial chylomicronemia syndrome.
• Analysis of current treatment strategies for hypertriglyceridemia in FCS.
• Evaluation of the efficacy of novel therapeutic agents, including ApoCIII antagonists and anti-ANGPTL3 therapies.

Main Results:

• Patients with FCS have impaired lipolytic capacity and poor response to conventional treatments.
• ApoCIII antagonists (volanesorsen, olezarsen, ARO-APOC3) show promise in lowering triglyceride levels.
• Anti-ANGPTL3 therapies appear less effective in current studies.

Conclusions:

• Familial chylomicronemia syndrome requires comprehensive management strategies.
• ApoCIII antagonists represent a promising therapeutic avenue for FCS.
• Further clinical trials and novel pharmacological treatments are essential to improve patient outcomes and quality of life.